This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

METabolic EXplorer Valuation

Is 7ME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7ME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 7ME's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7ME's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7ME?

Key metric: As 7ME is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 7ME. This is calculated by dividing 7ME's market cap by their current revenue.
What is 7ME's PS Ratio?
PS Ratio	0.04x
Sales	€168.17m
Market Cap	€6.16m

7ME key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	-1.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 7ME's PS Ratio compare to its peers?

The above table shows the PS ratio for 7ME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.7x
BIG1 Bio-Gate	0.9x	16.3%	€6.3m
BNN BRAIN Biotech	1.2x	8.5%	€69.9m
NTG Nabaltec	0.6x	5.1%	€122.8m
2HRA H&R GmbH KGaA	0.1x	3.0%	€128.4m
7ME METabolic EXplorer	0.04x	n/a	€6.2m

Price-To-Sales vs Peers: 7ME is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.7x).

Price to Sales Ratio vs Industry

How does 7ME's PS Ratio compare vs other companies in the DE Chemicals Industry?

4 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	1.0x	4.3%
7ME METabolic EXplorer	0.04x	n/a	US$6.72m
2HRA H&R GmbH KGaA	0.1x	3.0%	US$134.61m
NSAK OTI Greentech	0.03x	n/a	US$598.23k

4 Companies		Estimated Growth	Market Cap
Industry Avg.	1.0x	35.2%
7ME METabolic EXplorer	0.04x	n/a	US$6.72m

No more companies

Price-To-Sales vs Industry: 7ME is good value based on its Price-To-Sales Ratio (0x) compared to the European Chemicals industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is 7ME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7ME PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.04x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 7ME's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

UBE

JP¥241.7b

Engages in the chemicals, construction materials, and machinery businesses in Japan, North America, Europe, Africa, the Middle East, Thailand, India, Latin America, and internationally.

UBE

JP¥15.30

8.5%

7.7%

Tokuyama

JP¥197.6b

Produces and sells various chemical products in Japan.

TBT

JP¥16.70

5.0%

16.0%

Mitsubishi Chemical Group

JP¥1.2t

Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.

M3C

JP¥5.27

2.9%

-8.1%